124 search results for: Clinical Management
Current systemic therapies have been shown to induce remission in a subset of AD patients
Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.
Can early intervention modify the course of AD?
Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.
Early Intervention and the Potential for Disease Modification in Children With AD
This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Amy Paller discussing the benefits of early intervention for children with AD and the potential for disease modification. Dr. Paller also reviews available data investigating the impacts of therapies for AD on the disease itself and on associated comorbidities.
What is Early Intervention in AD?
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Eulàlia Baselga, Dr. Amy Paller, and Dr. Lisa Weibel share their views on what “early” means when discussing early intervention in AD.
Disease Modification in AD
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Amy Paller discusses the benefits of early intervention for children with AD and the potential for disease modification.
When is the right time to consider a biologic in patients with CRSwNP?
Prof. Hellings and Prof. Corso explain that the right time to implement a biologic depends on academic and reimbursement criteria, which vary by country.
Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission
Dr. Giorgio Canonica Regarding Multidisciplinary Approach
This video clip from the EAACI 2024 symposium highlights that a multidisciplinary approach is essential for the treatment of asthma.
Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?
This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.
What do we mean by disease control in AD?
Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.
On the Surface: Restoring the Skin Barrier in Patients with AD
In this clip from the April WCPD 2025 symposium, Dr Amy Paller highlights CCL17 (TARC) as an important biomarker in AD.
Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes
This infographic outlines how endotyping, phenotyping, and genotyping are interrelated concepts that are crucial for improving the way patients with COPD are characterized and how understanding these concepts can better optimize patient care
